Concourse Financial Group Securities, Inc. Harpoon Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share
Q2 2023 Aug 10, 2023	BUY	$0.55 - $0.82 $0 - $0
Q1 2023 May 15, 2023	BUY	$0.65 - $1.37 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$0.6 - $1.41 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$0.94 - $2.56 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$1.78 - $5.02 $0 - $0
Q1 2022 May 09, 2022	BUY	$3.54 - $8.08 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$5.69 - $7.83 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$7.88 - $14.0 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$13.81 - $23.25 $0 - $0
Q1 2021 May 13, 2021	BUY	$17.65 - $24.16 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$12.83 - $17.84 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$11.01 - $18.52 $0 - $0
Q2 2020 Aug 13, 2020	BUY	$11.11 - $24.72 $0 - $0
Q1 2020 May 13, 2020	BUY	$10.74 - $16.32 $0 - $0
Q4 2019 Feb 14, 2020	BUY	$12.94 - $20.58 $0 - $0
Q3 2019 Nov 13, 2019	BUY	$10.93 - $17.47 $0 - $0
Q2 2019 Aug 13, 2019	BUY	$10.0 - $13.03 $0 - $0
Q1 2019 May 15, 2019	BUY	$9.47 - $17.01 $0 - $0

Others Institutions Holding HARP

# of Institutions

Shares Held

353K

Call Options Held

Put Options Held

View Full List

About Harpoon Therapeutics, Inc.

Ticker HARP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,106,800
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candi...

More about HARP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account